The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]

What Happened?

On September 30, 2026, the U.S. District Court for the District of Delaware found that Liquidia’s lead commercial product used to treat pulmonary hypertension, Yutrepia inhalation powder, infringed two of six claims of United Therapeutics Corporation’s ‘327 patent. The Court ruled that Yutrepia infringed claims 1 and 14 of the ‘327 patent, which cover the treatment of pulmonary hypertension with interstitial lung disease patients with inhaled treprostinil. In response to the ruling, Luiqidia CEO Roger Jeffs stated, “We respectfully disagree with the Court’s decision regarding claims 1 and 14 and are fully prepared to pursue all available appellate options.” On this news, the price of Liquidia shares declined by $40.43 per share, or approximately 57.2%, from $70.69 per share on September 29, 2026 to close at $30.26 on September 30, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Liquidia securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261013222752/en/